Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Express Scripts
AstraZeneca
Colorcon
Medtronic

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ANTITHROMBIN III (HUMAN)

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for antithrombin iii (human)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00174902 ↗ The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress Unknown status Swiss National Science Foundation Phase 1/Phase 2 2003-10-01 This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00174902 ↗ The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress Unknown status Swiss Federal Institute of Technology Phase 1/Phase 2 2003-10-01 This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00262054 ↗ Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) Completed Deutsches Herzzentrum Muenchen Phase 4 2005-11-01 The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for antithrombin iii (human)

Condition Name

Condition Name for antithrombin iii (human)
Intervention Trials
Cardiopulmonary Bypass 3
Antithrombin III Deficiency 3
Covid19 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for antithrombin iii (human)
Intervention Trials
Antithrombin III Deficiency 8
Venous Thrombosis 7
Thrombosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for antithrombin iii (human)

Trials by Country

Trials by Country for antithrombin iii (human)
Location Trials
United States 62
Italy 14
Germany 7
United Kingdom 6
China 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for antithrombin iii (human)
Location Trials
New York 5
Florida 4
Arizona 4
California 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for antithrombin iii (human)

Clinical Trial Phase

Clinical Trial Phase for antithrombin iii (human)
Clinical Trial Phase Trials
Phase 4 27
Phase 3 12
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for antithrombin iii (human)
Clinical Trial Phase Trials
Completed 35
Unknown status 13
Recruiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for antithrombin iii (human)

Sponsor Name

Sponsor Name for antithrombin iii (human)
Sponsor Trials
rEVO Biologics 4
National Cancer Institute (NCI) 3
University of Vermont 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for antithrombin iii (human)
Sponsor Trials
Other 107
Industry 36
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Harvard Business School
Merck
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.